Origins

In 2014, Translational Genomics Research Institute’s (TGen’s) CLIA laboratory became Ashion Analytics, LLC. Ashion Analytics™ was originally developed using the clinical genomic sequencing and analysis technology utilized in the world’s first clinical studies for personalized cancer treatment. We continue to work with TGen® to provide clinical genomic sequencing for several important clinical studies.

We currently serve several externally funded molecular profiling clinical studies (pancreatic cancer, melanoma, multiple myeloma, neuroblastoma, lung cancer, brain cancer). Our goal is to accelerate the adoption of genomic analysis for clinical decision support to improve the treatment of patients with refractory, rare, or aggressive disease.

Capabilities

We are experts at Next-Generation Sequencing-based clinical laboratory services, derived from our pedigree from the pioneering precision medicine work at the Translational Genomics Research Institute® (TGen®) in Phoenix.

Tumor-normal exome sequencing

Tumor-normal targeted panel sequencing

RNA Sequencing

Nucleic acid extraction from FFPE tissue

Data analysis and technical reporting

Clinical Interpretation

All work is conducted by validated protocols in our CLIA-certified and CAP accredited laboratory.

Mission

Ashion Analytics™ Mission is to develop and deliver the premier personalized medicine diagnostic, data analytic, and clinical coordination services which assist healthcare providers in offering their patients individualized treatment options and which improve outcomes.

An improved understanding of genomics has the potential to fundamentally change the way we treat cancer, and improve the results where it matters… for patients. We are just beginning, but the future is very exciting.

Michael J. Demeure, M.D., MBA

Executive Vice President and General Manager of Ashion Analytics™